A Phase 1/2 interventional study of Hydroxychloroquine Sulfate Tablets and Placebo in Radiation-induced Oral Mucositis, sponsored by Xingchen Peng. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-04-29.
Sponsored by Xingchen Peng · Phase 1/2, Interventional, and Treatment
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Stomatitis with a site in China — 13 open to participants now, 13 under way, 2 of them phase 3. Stomatitis · China.
Among the 31 studies in Stomatitis with a site in China, this one is the 13th largest by planned enrollment of the 29 interventional ones that give a count, is one of 4 that started in 2024, is one of 2 in phase 1/2, reaches primary completion later than 4 of the 12 other live ones, and was the 22nd registered.
307 studies on the registry are indexed under Stomatitis; 74 are open to participants now.
Browse Stomatitis studies →13 of the 31 studies in Stomatitis with a site in China are open now. Recruiting first, the newest first:
West China Hospital · Sites in China
Ages 18–65
Sun Yat-sen University · Sites in China
Ages 18–70
West China Hospital · Sites in China
Ages 18–65
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18–65
Sun Yat-sen University · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 45 Stomatitis studies recruiting now, 20 (44%) set no upper age limit and 21 (47%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 14 · Phase 3 5 · Phase 4 2
First in 2013; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 158 is above the median of 60 across 277 interventional studies indexed under Stomatitis.
Median enrollment 138 across the 29 interventional studies, 285 across the 2 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 31 have an industry lead sponsor. The 10 most frequent:
Xingchen Peng is the lead sponsor of 8 studies on the registry; 4 are open to participants now.
Xingchen Peng has 1 study filed under Stomatitis — fewer than ten, so there is no comparison to draw.
5 of the studies in Stomatitis with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07311772Phase 3Sun Yat-sen UniversityPrevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid | 2027-03-15 |
| NCT07567742Sun Yat-sen UniversityTaurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma | 2027-03-30 |
| NCT07400328The First Affiliated Hospital of Soochow UniversityAmimestrocel Injection for Preventing Severe Oral Mucositis in HSCT Patients | 2027-05-31 |
| NCT07339774West China HospitalTraditional Chinese Medicine Preparation Alleviates Radiotherapy-induced Oral Mucositis in Head and Neck Cancer Patients. | 2027-05-31 |
| NCT07312656First Affiliated Hospital of Guangxi Medical UniversityAerosolized Mesenchymal Stem Cell-Derived Exosomes for the Prevention and Treatment of Radiation-Induced Oral Mucositis | 2027-06 |
Add all 5 to your calendar (.ics) → With an account.
Among the 31 studies in Stomatitis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Evaluate the safety, tolerance and efficacy of hydroxychloroquine sulfate tablets the prevention and treatment of oral mucositis and dysgeusia in patients undergoing radiotherapy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
use the placebo
Other: Placebo
use the hydroxychloroquine sulfate tablets
Drug: Hydroxychloroquine Sulfate Tablets
the trial group use the hydroxychloroquine sulfate tablets (200mg/time, bid)
the control group use the Placebo
the WHO grade of RIOM
use the WHO Oral Toxicity Scale to evaluate the WHO grade of RIOM. WHO O grade: no representation of RIOM; WHO 1 grade: soreness and erythema; WHO 2 grade: erythema, ulcers and ability to eat solids; WHO 3 grade: ulcers, requiring liquid diet; WHO 4 grade: alimentation not possible. The higher scores mean a worse outcome.
Time frame: From the start of radiotherapy to 8 weeks after completion of radiotherapy
Plan to share: No
Started Dec 2024 (actual). Primary completion is estimated for Jun 2025, 5 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hydroxychloroquine
Xingchen Peng